PF-Atlas › Исследования › FDA Approved 2025
Исследования: FDA Approved 2025 (6)
6 публикаций в теме «FDA Approved 2025», проиндексированных PF-Atlas из PubMed и мировых журналов.
- Jascayd : a novel PDE4B inhibitor for idiopathic pulmonary fibrosis. · Annals of medicine and surgery (2012) · 2026
- Nerandomilast attenuates Pantoea agglomerans-induced hypersensitivity pneumonitis by regulating M1 macrophage polarization and fibroblast activation. · Respiratory research · 2026
- Precision Modulation of the PDE4 Pathway: The Emerging Role of Nerandomilast in Pulmonary Fibrosis. · The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026
- [Management of Progressive Pulmonary Fibroses - 2025 Update]. · Deutsche medizinische Wochenschrift (1946) · 2026
- Nerandomilast Improves Bleomycin-Induced Systemic Sclerosis-Associated Interstitial Lung Disease in Mice by Regulating the TGF-β1 Pathway. · Inflammation · 2025
- Nerandomilast. · 2012
Медицинская оговорка. Списки исследований приведены только для информации и не являются медицинской рекомендацией.